Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19

Leukemia. 2021 Sep;35(9):2710-2714. doi: 10.1038/s41375-021-01299-x. Epub 2021 May 24.
No abstract available

Publication types

  • Letter
  • Observational Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents, Immunological / therapeutic use
  • C-Reactive Protein / genetics
  • C-Reactive Protein / metabolism*
  • COVID-19 / immunology
  • COVID-19 / therapy*
  • COVID-19 / virology
  • COVID-19 Drug Treatment
  • Humans
  • Interleukin-8 / antagonists & inhibitors
  • Interleukin-8 / blood*
  • Prospective Studies
  • SARS-CoV-2 / drug effects*
  • SARS-CoV-2 / isolation & purification
  • SARS-CoV-2 / pathogenicity
  • Serum Amyloid P-Component / genetics
  • Serum Amyloid P-Component / metabolism*
  • Survival Rate
  • Ventilators, Mechanical*

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents, Immunological
  • Interleukin-8
  • Serum Amyloid P-Component
  • PTX3 protein
  • C-Reactive Protein
  • siltuximab